These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 34953520)

  • 1. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
    ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group
    Lancet Infect Dis; 2022 May; 22(5):622-635. PubMed ID: 34953520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.
    Brown SM; Barkauskas CE; Grund B; Sharma S; Phillips AN; Leither L; Peltan ID; Lanspa M; Gilstrap DL; Mourad A; Lane K; Beitler JR; Serra AL; Garcia I; Almasri E; Fayed M; Hubel K; Harris ES; Middleton EA; Barrios MAG; Mathews KS; Goel NN; Acquah S; Mosier J; Hypes C; Salvagio Campbell E; Khan A; Hough CL; Wilson JG; Levitt JE; Duggal A; Dugar S; Goodwin AJ; Terry C; Chen P; Torbati S; Iyer N; Sandkovsky US; Johnson NJ; Robinson BRH; Matthay MA; Aggarwal NR; Douglas IS; Casey JD; Hache-Marliere M; Georges Youssef J; Nkemdirim W; Leshnower B; Awan O; Pannu S; O'Mahony DS; Manian P; Awori Hayanga JW; Wortmann GW; Tomazini BM; Miller RF; Jensen JU; Murray DD; Bickell NA; Zatakia J; Burris S; Higgs ES; Natarajan V; Dewar RL; Schechner A; Kang N; Arenas-Pinto A; Hudson F; Ginde AA; Self WH; Rogers AJ; Oldmixon CF; Morin H; Sanchez A; Weintrob AC; Cavalcanti AB; Davis-Karim A; Engen N; Denning E; Taylor Thompson B; Gelijns AC; Kan V; Davey VJ; Lundgren JD; Babiker AG; Neaton JD; Lane HC;
    Lancet Respir Med; 2023 Sep; 11(9):791-803. PubMed ID: 37348524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.
    ITAC (INSIGHT 013) Study Group
    Lancet; 2022 Feb; 399(10324):530-540. PubMed ID: 35093205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
    Kalil AC; Mehta AK; Patterson TF; Erdmann N; Gomez CA; Jain MK; Wolfe CR; Ruiz-Palacios GM; Kline S; Regalado Pineda J; Luetkemeyer AF; Harkins MS; Jackson PEH; Iovine NM; Tapson VF; Oh MD; Whitaker JA; Mularski RA; Paules CI; Ince D; Takasaki J; Sweeney DA; Sandkovsky U; Wyles DL; Hohmann E; Grimes KA; Grossberg R; Laguio-Vila M; Lambert AA; Lopez de Castilla D; Kim E; Larson L; Wan CR; Traenkner JJ; Ponce PO; Patterson JE; Goepfert PA; Sofarelli TA; Mocherla S; Ko ER; Ponce de Leon A; Doernberg SB; Atmar RL; Maves RC; Dangond F; Ferreira J; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd L; Tomashek KM; Beigel JH;
    Lancet Respir Med; 2021 Dec; 9(12):1365-1376. PubMed ID: 34672949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.
    ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group
    Lancet Respir Med; 2022 Oct; 10(10):972-984. PubMed ID: 35817072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
    Wolfe CR; Tomashek KM; Patterson TF; Gomez CA; Marconi VC; Jain MK; Yang OO; Paules CI; Palacios GMR; Grossberg R; Harkins MS; Mularski RA; Erdmann N; Sandkovsky U; Almasri E; Pineda JR; Dretler AW; de Castilla DL; Branche AR; Park PK; Mehta AK; Short WR; McLellan SLF; Kline S; Iovine NM; El Sahly HM; Doernberg SB; Oh MD; Huprikar N; Hohmann E; Kelley CF; Holodniy M; Kim ES; Sweeney DA; Finberg RW; Grimes KA; Maves RC; Ko ER; Engemann JJ; Taylor BS; Ponce PO; Larson L; Melendez DP; Seibert AM; Rouphael NG; Strebe J; Clark JL; Julian KG; de Leon AP; Cardoso A; de Bono S; Atmar RL; Ganesan A; Ferreira JL; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd LE; Beigel JH; Kalil AC;
    Lancet Respir Med; 2022 Sep; 10(9):888-899. PubMed ID: 35617986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
    Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
    Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
    ; Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Davey VJ; Goodman A; Higgs ES; Murray DD; Murray TA; Paredes R; Parmar MKB; Phillips AN; Reilly C; Sharma S; Dewar RL; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD
    N Engl J Med; 2021 Mar; 384(10):905-914. PubMed ID: 33356051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
    Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Falci DR; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Hebner CM; Sager J; Mogalian E; Tipple C; Peppercorn A; Alexander E; Pang PS; Free A; Brinson C; Aldinger M; Shapiro AE;
    N Engl J Med; 2021 Nov; 385(21):1941-1950. PubMed ID: 34706189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
    Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
    Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.
    Welker J; Pulido JD; Catanzaro AT; Malvestutto CD; Li Z; Cohen JB; Whitman ED; Byrne D; Giddings OK; Lake JE; Chua JV; Li E; Chen J; Zhou X; He K; Gates D; Kaur A; Chen J; Chou HY; Devenport M; Touomou R; Kottilil S; Liu Y; Zheng P;
    Lancet Infect Dis; 2022 May; 22(5):611-621. PubMed ID: 35286843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
    Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
    Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
    Davey RT; Fernández-Cruz E; Markowitz N; Pett S; Babiker AG; Wentworth D; Khurana S; Engen N; Gordin F; Jain MK; Kan V; Polizzotto MN; Riska P; Ruxrungtham K; Temesgen Z; Lundgren J; Beigel JH; Lane HC; Neaton JD;
    Lancet Respir Med; 2019 Nov; 7(11):951-963. PubMed ID: 31582358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
    Montgomery H; Hobbs FDR; Padilla F; Arbetter D; Templeton A; Seegobin S; Kim K; Campos JAS; Arends RH; Brodek BH; Brooks D; Garbes P; Jimenez J; Koh GCKW; Padilla KW; Streicher K; Viani RM; Alagappan V; Pangalos MN; Esser MT;
    Lancet Respir Med; 2022 Oct; 10(10):985-996. PubMed ID: 35688164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
    JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
    ; Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Goodman AL; Chang W; Dewar RL; Gerry NP; Higgs ES; Highbarger H; Murray DD; Murray TA; Natarajan V; Paredes R; Parmar MKB; Phillips AN; Reilly C; Rupert AW; Sharma S; Shaw-Saliba K; Sherman BT; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Davey VJ; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD
    Ann Intern Med; 2022 Feb; 175(2):234-243. PubMed ID: 34928698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.